Gerson Lehrman Group - Intelligently Connecting Institutions and Expertise.

Contributing Member of the Healthcare Councils

Names and details of certain GLG News authors are available only to GLG Clients and Council Members. GLG News authors are subject-matter experts within the GLG Councils and are available for expert consulting - by phone, in-person, or written analysis. To find out how to become a GLG client or Council Member, click here.

GLG News by this Author

Analyses are solely the work of the authors and have not been edited or endorsed by GLG.

Critical thinking and creativity in AD research

November 9, 2009

New Treatment Halts Progress of Alzheimer's Disease | www.abdn.ac.uk

The recetn  clinical results suggest that plaque removal is not enough to halt progressive neurodegeneration in Alzheimer Disease and prompt some intriguing challenges to the amyloid hypothesis.

We need to learn more about ProSavin Phase I/II Trial in Parkinson’s disease

October 20, 2009

Oxford BioMedica Announces Update on ProSavin® Phase I/II Trial in Parkinsons Disease And Publication of Preclinical Results | www.pipelinereview.com

This is very interesting news. However, in my judgment it is too early to make a final conclusion concerning this clinical trial. Because it should be taken into account that the growing body of evidence clearly indicates that oxidative stress induced mitochondrial failure appeared to be one of the main reasons for the selective neuronal damages that occurs in Parkinson’s disease. 

Amyloid Beta does not correlate to Alzheimer Disease.

October 12, 2009

Bayer Schering ties-up with AC Immune for trial in Alzheimer´s disease | www.pharmabiz.com

The finding of amyloid-beta (Aβ) deposition in AD brains after death led to the so-called “amyloid hypothesis”.  We have extensively reviewed the literature which claims that AD is caused by the deposition of Aβ within structures called senile plaques that invade AD brains and that such plaque formation then leads to further abnormalities within the nerve cells, eventually killing them.

Page : 11 to 3 of 3

Subscribe to Updates

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines

This author consults with leading institutions through GLG